ABOUT US About Celltrion Notice Media Center BUSINESS Business Areas R&D Production Distribution PRODUCTS Products Pipeline ESG Environmental Social Governance ESG Archive IR Financial Information Stock Summary Public Disclosures IR Archive CAREERS Our Values How to Apply Jobs KOR ENG Choose All Languages Europe Asia Pacific North America Latin America close Finland (FI) Finland (SV) France Germany Hungary Ireland Italy Netherlands Turkey United Kingdom Korea (HQ) Korea (EN) Japan Australia Canada (EN) Canada (FR) USA Brazil Colombia Chile Peru Mexico
Category IR Approvals General Other All Title Content delete search General Latest Developments Regarding the Agreement with PBMs for Yuflyma 2024.04.11 General Response to Inquiries Regarding the Inclusion of Zymfentra in PBM Formularies 2024.04.08 General Notice to shareholders 2022.09.15 General Notice to shareholders regarding: The conclusion of the financial regulator’s audit inspection and the Securities & Futures Commission’s review 2022.03.11 General Celltrion’s Statement on the development of a therapeutic antibody treatment to combat COVID-19 2020.04.13 General Celltrion receives EIR from the FDA 2018.09.18 General Celltrion’s Statement on a recent form 483 from the U.S. FDA 2018.08.07 General Notification of resubmission for biosimilar candidate CT-P10 for FDA review 2018.05.30 General Celltrion’s Statement on CRLs from the U.S. FDA for rituximab and trastuzumab biosimilar 2018.04.06 General Celltrion’s Statement on Warning Letter Issued for its Drug Manufacturing Facility 2018.02.01 First 1 2 Last